Hydroxyurea (Hydrea)

Subscribe to Selected New Research on Hydroxyurea

1911 relevant articles (119 outcomes, 250 trials/studies) found for this Drug

Description: An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Also Known As:

Hydrea; Oncocarbide; Hydroxycarbamid; Urea, hydroxy-

Relationship Network

Drug Context: Research Results

Experts

1.	Ware, Russell E: 8 articles (02/2008 - 01/2002)
2.	Haraf, Daniel J: 5 articles (04/2008 - 01/2003)
3.	Vokes, Everett E: 5 articles (04/2008 - 01/2003)
4.	Wang, Winfred C: 5 articles (02/2008 - 01/2002)
5.	Stenson, Kerstin: 4 articles (04/2008 - 01/2003)
6.	Witt, Mary Ellyn: 4 articles (04/2008 - 01/2003)
7.	Zimmerman, Sherri A: 4 articles (08/2007 - 04/2003)
8.	Wadler, Scott: 4 articles (01/2007 - 03/2002)
9.	Weichselbaum, Ralph R: 3 articles (04/2008 - 01/2003)
10.	Barbui, T: 3 articles (02/2007 - 09/2000)

Related Diseases

1.	Sickle Cell Anemia (Hemoglobin S Disease) 07/01/1997 - "Children with sickle cell anemia provide the best opportunity to assess the efficacy of hydroxyurea (HU) in preventing complications and progressive organ damage. " 11/01/1997 - "Although hydroxyurea has been effective in the treatment of sickle-cell anemia, large double-blind, placebo-controlled clinical trials are needed to determine whether the risks of long-term administration outweight the risk of vaso-occlusive disease in untreated patients." 06/01/2008 - "Hydroxyurea has documented laboratory and clinical efficacy for children with sickle cell anemia (SCA), and has potential to become an effective and inexpensive treatment option for patients in countries with limited resources. " 02/01/2002 - "OBJECTIVES: Although hydroxyurea is effective in treating adults with sickle-cell anemia (SCA), there is concern that it may adversely affect growth in children. " 08/01/2002 - "In a published randomized clinical trial, hydroxyurea (HU) improved clinical outcomes in patients with sickle cell anemia (SCA). " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 08/01/2000 - "In this study, we have observed an interesting effect of hydroxyurea on tumor cells: an induction of senescence-like changes. " 07/05/1994 - "Since previous studies have shown that low concentrations of hydroxyurea (HU) can eliminate DMs, we studied the use of HU as a gene-targeting agent in tumor cells containing extrachromosomally amplified oncogenes. " 06/01/1992 - "With the conclusion of some current trials, it is conceivable that the use of hydroxyurea may be more clearly defined in the treatment of tumors affecting the nervous system." 04/15/1985 - "Both studies would suggest that pelvic radiation plus hydroxyurea improves the rate of survival in patients with Stage IIB cervical cancer." 06/01/1970 - "Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065)." Order ALL the reference details at left...
3.	Essential Thrombocythemia 03/01/2009 - "A 72-year-old man was diagnosed with essential thrombocythemia (ET) and was treated with hydroxyurea for approximately 5 years. " 08/01/2008 - "Hydroxyurea in old patients with essential thrombocythemia." 05/01/2008 - "JAK2V617F-positive patients with essential thrombocythemia, as opposed to their mutation-negative counterparts, require lower doses of hydroxyurea (HU) for control of their platelet count. " 02/01/2007 - "A widely accepted definition of resistance or intolerance to hydroxyurea (HU) in patients with essential thrombocythemia (ET) is lacking. " 02/01/2007 - "A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group." Order ALL the reference details at left...
4.	Polycythemia Vera 02/01/1998 - "To manage the current case of polycythemia vera, hydroxyurea was effective for the control of hematocrit and transfusion of platelet concentrates was effective for hemostasis." 03/01/1987 - "Because hydroxyurea is safe and effective in the treatment of polycythemia vera, it should be considered as first-line therapy. " 08/01/2006 - "The cytoreductive agent of choice for these disorders is currently hydroxyurea, emerging from randomized trials beginning with those of the Polycythemia Vera Study Group. " 01/01/1997 - "From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera." 10/01/2009 - "[Cutaneous side effects of hydroxyurea treatment for polycythemia vera]" Order ALL the reference details at left...
5.	Thrombosis (Thrombus) 01/01/2007 - "Hydroxyurea is effective in preventing thrombosis in high-risk patients with essential thrombocythaemia. " 09/01/2001 - "The use of hydroxyurea in high-risk patients with ET has reduced the incidence of thrombosis, and recent studies have suggested the value of keeping the platelet count below 400 x 10(9)/L in such cases. " 10/01/2008 - "A 21-year-old man with homozygous sickle cell disease maintained on hydroxyurea for 1 year developed thrombosis of the superior sagittal, right transverse, and right sigmoid dural sinuses with a large venous infarct. " 08/01/2008 - "METHODS: We compared the clinical outcome of 27 ET old patients not taking cytotoxic drugs (group A) with 27 cases treated with hydroxyurea (HU) (group B), evaluating the incidence of thrombosis and thrombosis-free survival. " 06/15/2007 - "Cytotoxic therapy is indicated in high-risk patients, and the drug of choice is hydroxyurea because of its efficacy in preventing thrombosis and low leukemogenicity. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Fetal Hemoglobin (Hemoglobin F)
2.	anagrelide (Agrylin)
3.	Busulfan (Busulfex)
4.	Interferon-alpha (Interferon Alfa)
5.	Aspirin (Acetylsalicylic Acid)
6.	Ribonucleotide Reductases (Ribonucleotide Reductase)
7.	Cytarabine (Cytosar-U)
8.	Vincristine (Oncovin)
9.	imatinib (Gleevec)
10.	Thioguanine (Tioguanine)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplantation (Transplant Recipients)
3.	Blood Transfusion (Blood Transfusions)
4.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
5.	Liver Transplantation

Best Treatments:
Research Summary Report
on Sickle Cell Anemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 56 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>